Liver
The Latest
Endohepatology expands clinical reach
-
by Doug Brunk
Review details performance data, comparative trials, and persistent gaps as EUS moves deeper into hepatology practice.
Endoscopic ultrasound pushes beyond biopsy in diagnostics
-
by Doug Brunk
Review highlights advances that expand endoscopic ultrasound into precision diagnostics and personalized therapy across pancreatic and liver diseases.
Combination therapy shows promise for hepatitis D in phase 2 trial
-
by Amy Pfeiffer
"Tobevibart and elebsiran have complementary mechanisms of action."
Global MASH costs set to double by 2040
-
by Doug Brunk
A multinational modeling study projects sharp rises in advanced liver disease, deaths and health care spending tied to MASH across nine countries.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
Tiny plastics may harm gut and liver health, review finds
-
by Doug Brunk
“Our aim was to start conversations between clinicians and their patients about this emerging risk,” Dr. Priyata Dutta explained.
ACA expansion linked to better liver disease outcomes
-
by Doug Brunk
The analysis is believed to be the first of its kind.
VCTE vs histology in MASLD, study findings
-
by Doug Brunk
The study included 3,532 adults with MASLD.
Cirrhosis, age may shape HCC risk in PSC
-
by Doug Brunk
Investigators followed 3,071 patients for a mean of 12.5 years.
Positive trends in chronic HCV mortality
-
by Doug Brunk
“DAAs have revolutionized the management of HCV by making it a curable disease.”
Tirzepatide tops semaglutide for cardiometabolic protection in MASLD
-
by Doug Brunk
The study authors recommend prospective head-to-head trials to validate the findings.
ALD-related HCC mortality surges
-
by Doug Brunk
The findings underscore the urgent need for targeted prevention strategies among high-risk group.
New score challenges old predictors
-
by Kerri Miller
"MERAGE has superior performance for predicting return to drinking (RTD) compared to HRAR in AH."
Approach to weight management in GI practice
-
by Colleen R. Kelly, MD
As gastroenterologists, we treat a number of conditions that are caused or worsened by obesity.
Exercise patterns and GI cancer risk
-
by Kerri Miller
Consistently meeting—but not exceeding—recommended activity levels offers maximal protection against digestive cancers, new research suggests.
AGA issues updated guidance on HDV management
-
by Amy Pfeiffer
An AGA panel recommended universal HDV screening for all patients with chronic HBV infection.
Sarcopenia, thrombosis, and renal dysfunction dominate cirrhosis complication updates
-
by Kerri Miller
New diagnostic approaches and treatment controversies emerge for managing advanced liver disease complications.
Open vs robotic liver resections, study results
-
by Teraya Smith
Complication rates and hospital stays were analyzed across both surgical groups.
Clinical research in early career academic medicine
-
by Lauren D. Feld, MD, Kathy Nguyen, Katherine Cooper, MD, Loren Galler Rabinowitz, MD, Amiko M. Uchida, MD
Alcohol hepatitis: Why females face higher risks
-
by Kathryn Wighton
Study reveals rising hepatitis rates in young adults, with females facing greater risks of cirrhosis and liver-related death
How to discuss lifestyle modifications in MASLD
-
by Newsha Nikzad, MD, Daniel J. Huynh, BS, Nikki Duong, MD
Achieving promotion for junior faculty in academic medicine: An interview with experts
-
by Vineet S. Rolston, MD, Sophie Balzora, MD, Mark A. Schattner, MD
Hepatologist finds purpose as health equity advocate for LGBTQI+
-
by Jennifer Lubell
“As I was going through training, I didn’t think others like me existed, a gay South Asian transplant hepatologist."
Statins and the liver: Not harmful and perhaps beneficial
-
by Paul Martin, MD, Lawrence S. Friedman, MD
Recruiting gastroenterology and hepatology fellows virtually - Should we continue after the pandemic?
-
by Lara Dakhoul, MD, Tiffany Rhoden, Virginia Clark, MD
Immune checkpoint inhibitor–related gastrointestinal adverse events
-
by Joshua Kwon, MD, Paul T. Kröner, MD, MSc
From the editor: Building community - Introducing Member Spotlight
-
by Megan A. Adams, MD, JD, MSc
Cell-free DNA testing shows promise for early liver cancer detection
-
by Doug Brunk
Methylation-based cfDNA assays appear particularly promising.
